AgingResearch.NewsJoin free

QED Therapeutics

Part of BridgeBio

CompanyUnited States

QED Therapeutics develops one asset, approved (infigratinib). Mostly small molecule acting on FGFR1, FGFR4 and fgfr3; based in the United States.

1
Asset
Furthest stage
Approved
2
Trials
0
Signals

Pipeline

1

  • infigratinib

    Inhibits FGFR tyrosine kinases, reducing excessive FGFR3 signaling that impairs bone growth in achondroplasia.

    Approved, Small molecule, FGFR1, FGFR4, advanced cholangiocarcinoma (Phase 3), fgfr2 gene mutation (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials3
  • Signals4
  • Similar companies6

Intelligence